Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K45/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220306646Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors
US 29.09.2022
Int.Class C07D 495/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
495Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 17215468 Applicant Daljit Singh Dhanoa Inventor Daljit Singh Dhanoa

The present invention is concerned with novel deuterated Angiotensin-Converting Enzyme-2 (ACE-2) inhibitors of general structural formula I, their optically active enantiomers and diastereoisomers, and pharmaceutical salts and compositions thereof, as well as combination therapies which include compounds of the present invention,

embedded image

These compounds have high potency and selectivity for Angiotensin-Converting Enzyme-2 (ACE-2) inhibition, and are useful in the treatment of infectious respiratory diseases including the pandemic disease Covid-19, Severe Acute Respiratory Syndrome (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS-CoV), and other diseases caused by coronaviruses.

2.20220304984AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF
US 29.09.2022
Int.Class A61K 31/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
Appl.No 17618829 Applicant VANDERBILT UNIVERSITY Inventor H. Charles Manning

These compounds are glutamine transporter inhibitors, e.g., alanine, serine, cysteine-preferring transporter 2 (ASCT2) inhibitors. Glutamine transporter inhibitors are useful to treat a variety of diseases, disorders, or conditions including cancer.

3.20220305078PEPTIDES AND METHODS OF USE THEREOF IN TREATING UVEITIS
US 29.09.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No 17619168 Applicant BIOMARCK PHARMACEUTICALS LTD. Inventor Indu PARIKH

The present disclosure includes methods of treating ocular inflammation or inflammatory ocular conditions, such as uveitis. More specifically the present disclosure relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present disclosure includes an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof as disclosed in the present disclosure are useful in such methods.

4.20220306639PHARMACEUTICAL COMPOUNDS
US 29.09.2022
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 17636510 Applicant ReViral Limited Inventor George Stuart COCKERILL

Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, custom-character and custom-character are bonds, and custom-character and custom-character are absent; or (ii) T is C, Z is N, custom-character and custom-character are bonds, and custom-character and custom-character are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7, —COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

embedded image

5.WO/2022/200334NUTRACEUTICAL COMPOSITION COMPRISING INULIN FOR TREATING AND PREVENTING OCULAR DISORDERS OR INTESTINAL MICROBIOTA IMBALANCE
WO 29.09.2022
Int.Class A61K 31/205
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
Appl.No PCT/EP2022/057466 Applicant OPHTALMIS Inventor CLARET, Martine
The present invention relates to a nutraceutical composition comprising inulin and a Chilean wineberry extract, and also other ingredients such as amino acids, vitamins and/or trace elements, in particular for the use thereof in preventing and/or treating ocular pathological conditions and/or in preventing and/or treating intestinal microbiota imbalances.
6.WO/2022/200574IMMUNOGENIC COMPOSITIONS
WO 29.09.2022
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
Appl.No PCT/EP2022/057933 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor VASSILEV, Ventzislav Bojidarov
The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.
7.WO/2022/204084METHODS AND COMPOSITIONS FOR INHIBITING FORMATION OF THE HIV LATENT RESERVOIR
WO 29.09.2022
Int.Class A61K 31/167
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
167having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Appl.No PCT/US2022/021259 Applicant THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Inventor MARGOLIS, David
The present invention relates to methods for inhibiting human immunodeficiency virus (HIV) from entering latency in an infected subjected by co-administering an antiretroviral therapy regimen (ART) and a histone deacetylase (HDAC) inhibitor during a time window suitable for inhibiting entry into latency. The invention further relates to methods for treating HIV infections and compositions for carrying out the methods of the invention.
8.WO/2022/204504VIRAL VECTORS WITH REDUCED IMMUNOGENICITY
WO 29.09.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/US2022/021929 Applicant CORNELL UNIVERSITY Inventor JIANG, Shaoyi
Compositions and methods for modified viral vectors which mitigate the immunogenicity of viral vectors, enabling multiple administrations of viral-based gene delivery viral vectors are described herein. The viral vectors advantageously possess low immunogenicity and comprise at least one immunosuppressive moiety. Also described herein are methods for introducing genetic material into a cell. Additionally, described herein are methods for preparing a modified viral vector. Lastly, described herein are methods for treating a subject, the method comprising administering to a subject a modified viral vector composition as described above.
9.20220304976Method of simultaneously treating viral disease caused coronavirus, its variants and mutants using a pharmaceutical micronutrient composition
US 29.09.2022
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No 17728769 Applicant MATTHIAS W RATH Inventor Aleksandra Niedzwiecki

A method of preventing, inhibiting and treating a mammal suffering from viral infections using a pharmaceutical micronutrient composition including mixture D is disclosed. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Mixture D and seemed to have beneficial effects to prevent and treat diseases where viruses use the angiotensin converting enzyme 2 (ACE2) receptor on the surface of epithelial cells, endothelial cells and other cell types for viral entry.

10.20220305029Pharmaceutical composition for inhibiting the infectivity of lipid bilayer viruses, treating associated diseases and their complications
US 29.09.2022
Int.Class A61K 31/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Appl.No 17700547 Applicant Guy Faustin MONKAM NITCHEU Inventor Guy Faustin MONKAM NITCHEU

This invention related to a pharmaceutical composition which can be used as an anti-infective on enveloped pathogens and their various complications.